Hydrazone derivatives for preventing or treating EBV-related cancers
US11406631B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 3, 2019 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | Apr 18, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2− and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.